Compare Ginkgo Bioworks Holdings Inc (DNA) vs New York Times Co (NYT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs New York Times Co — how do they compare? Ginkgo Bioworks Holdings Inc trades at $9.06 (market cap $590.53M), while New York Times Co trades at $73.2 (market cap $11.81B). The key difference: New York Times Co is far larger — about 20× Ginkgo Bioworks Holdings Inc's market cap, and New York Times Co pays a 1.26% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.
| DNA | NYT | |
|---|---|---|
Market Cap | $590.53M | $11.81B |
Sector | Health | Media |
52-Week High | $16.14 | $85.86 |
52-Week Low | $5.48 | $51.43 |
Enterprise Value | $627.78M | $11.21B |
Dividend Yield | — | 1.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DNA trades at $9.05, down 0.44% on the day, reflecting ongoing investor caution. The technical outlook is bearish, while fundamentals show significant losses with a net income margin of -201.05% and negative cash flows. Recent earnings have been mixed, missing estimates in two of the last three quarters. Analyst sentiment is divided, with a slight lean toward buy ratings amid high volatility and operational challenges.
The outlook remains challenging due to persistent losses and cash burn, though analyst coverage suggests potential long-term value. Key risks include execution missteps and intense competition in biotechnology. Investment appeal hinges on future profitability improvements and successful business model execution.
The New York Times (NYT) stock trades at $75.04, up 0.11% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company shows strong fundamentals with revenue growth from $2.3B in 2022 to $2.8B in 2025 and net income margin improving to 12.17%. Recent earnings beats and a 29.41% analyst buy rating support positive sentiment, though legal and regulatory pressures from ongoing subpoenas and copyright disputes with OpenAI present near-term risks.
Outlook remains cautiously optimistic with a consensus price target of $78.00, offering ~4% upside. Investment opportunities include consistent earnings growth and defensive stock characteristics amid market volatility. Key risks involve legal overhangs from government subpoenas and AI copyright litigation, which could impact operational focus and financial performance if prolonged.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About New York Times Co
New York Times Co is an American media company known for publishing its flagship newspaper, The New York Times. The company also operates the International New York Times newspaper, as well as digital properties such as nytimes and various smartphone applications. Circulation of The New York Times is the source of revenue for the company, followed by print and digital advertising and its paid digital-only subscription to The New York Times. The company has a daily print circulation of over 500,000 and 1,000,000 on Sundays. The source of growth for The New York Times is its digital subscription service, which has over 1,000,000 paid users.
Read more on NYT →
